RxDoctor Payments Data

Billie Russell

Psychiatric/Mental Health · Sumiton, ALNPI 1063836807

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations.

$6,336in general payments, 2019–2025

Across 290 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$837
  • Supernus Pharmaceuticals, Inc.$600
  • Alkermes, Inc.$462
  • Axsome Therapeutics, Inc.$425
  • plus $2K from 9 others

What the payments were for

  • Food & beverage$6,25799%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,336 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl17$34,464
CaplytaLumateperone Tosylate14$25,264
RexultiBrexpiprazole11$16,052
TrintellixVortioxetine Hydrobromide15$11,683
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine28$1,342
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine36$1,050
Aripiprazole18$1,019
Bupropion XlBupropion Hcl45$991
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$882
Duloxetine Hcl53$665
Quetiapine Fumarate43$639
Hydroxyzine Hcl22$486
Trazodone Hcl32$419
Fluoxetine Hcl30$313
Buspirone Hcl41$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,220$34,46417 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,097$25,26414 claims
Otsuka America Pharmaceutical, Inc.Rexulti$837$16,05211 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$417$11,68315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Sumiton

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →